PDF herunterladen
Thromb Haemost 2003; 89(05): 949-950
DOI: 10.1055/s-0037-1613486
Letters to the Editor
Schattauer GmbH

The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements

H. Hickmott
,
H. Wynne
,
F. Kamali
Weitere Informationen

Publikationsverlauf

Received 16. September 2002

Accepted after revision 26. Februar 2003

Publikationsdatum:
09. Dezember 2017 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Collins R, Peto R, Armitage J.. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56: 53-6.
    PubMedGoogle Scholar
  • 2 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
    CrossrefPubMedGoogle Scholar
  • 3 Walker JF.. Simvastatin: the clinical profile. Am J Med 1987; 87 4A 445-65.
    PubMedGoogle Scholar
  • 4 Keech A, Collins R, MacMahon S.. et al. Three-year follow up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
    CrossrefPubMedGoogle Scholar
  • 5 Feely J, O'Connor P.. Effects of HMG-Co A reductase inhibitors on warfarin binding. Drug Invest 1991; 5: 315-36.
    PubMedGoogle Scholar
  • 6 Transon C, Leeman T, Dayer P.. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-Co A reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15.
    CrossrefPubMedGoogle Scholar
  • 7 Packard CJ.. Effects of drugs on postprandial lipid metabolism. Proc Nutr Soc 1997; 56: 745-51.
    CrossrefPubMedGoogle Scholar